File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Pentasomy 8q in therapy-related myelodysplastic syndrome due to cyclophosphamide therapy for fibrosing alveolitis

TitlePentasomy 8q in therapy-related myelodysplastic syndrome due to cyclophosphamide therapy for fibrosing alveolitis
Authors
Issue Date2003
PublisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/cancergene
Citation
Cancer Genetics And Cytogenetics, 2003, v. 141 n. 1, p. 79-82 How to Cite?
AbstractTrisomy 8/8q is a common cytogenetic event in myelocytic malignancies, ranging from myelodysplastic syndrome (MDS) to acute myelocytic leukemia (AML) to blastic transformation of chronic myelocytic leukemia. Isochromosome 8q results in the same gene dosage effect. Duplication of i(8q), resulting in pentasomy 8q, has been reported only in two cases of AML. A patient with fibrosing alveolitis on prolonged cyclophosphamide treatment developed therapy-related MDS. Karyotyping, FISH, and CGH analysis showed a duplicated i(8q) among other complex abnormalities. The clinical features of 11 cases of myelocytic leukemia with pentasomy and hexasomy 8/8q were summarized. Compared with trisomy and tetrasomy 8, significant features included reduced median survival (90 days), treatment refractoriness (even with transplantation), monocytic differentiation, trilineage dysplasia, and radiation or toxin exposure. Increasing copy numbers of chromosome 8/8q may therefore be a marker of advanced leukemic evolution, exposure to toxins, underlying myelodysplasia, and an overall poor prognosis. © 2003 Elsevier Science Inc. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/78735
ISSN
2012 Impact Factor: 1.929
2013 SCImago Journal Rankings: 0.872
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorAu, WYen_HK
dc.contributor.authorMa, SKen_HK
dc.contributor.authorWan, TSen_HK
dc.contributor.authorMan, Cen_HK
dc.contributor.authorKwong, YLen_HK
dc.date.accessioned2010-09-06T07:46:09Z-
dc.date.available2010-09-06T07:46:09Z-
dc.date.issued2003en_HK
dc.identifier.citationCancer Genetics And Cytogenetics, 2003, v. 141 n. 1, p. 79-82en_HK
dc.identifier.issn0165-4608en_HK
dc.identifier.urihttp://hdl.handle.net/10722/78735-
dc.description.abstractTrisomy 8/8q is a common cytogenetic event in myelocytic malignancies, ranging from myelodysplastic syndrome (MDS) to acute myelocytic leukemia (AML) to blastic transformation of chronic myelocytic leukemia. Isochromosome 8q results in the same gene dosage effect. Duplication of i(8q), resulting in pentasomy 8q, has been reported only in two cases of AML. A patient with fibrosing alveolitis on prolonged cyclophosphamide treatment developed therapy-related MDS. Karyotyping, FISH, and CGH analysis showed a duplicated i(8q) among other complex abnormalities. The clinical features of 11 cases of myelocytic leukemia with pentasomy and hexasomy 8/8q were summarized. Compared with trisomy and tetrasomy 8, significant features included reduced median survival (90 days), treatment refractoriness (even with transplantation), monocytic differentiation, trilineage dysplasia, and radiation or toxin exposure. Increasing copy numbers of chromosome 8/8q may therefore be a marker of advanced leukemic evolution, exposure to toxins, underlying myelodysplasia, and an overall poor prognosis. © 2003 Elsevier Science Inc. All rights reserved.en_HK
dc.languageengen_HK
dc.publisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/cancergeneen_HK
dc.relation.ispartofCancer Genetics and Cytogeneticsen_HK
dc.rightsCancer Genetics and Cytogenetics. Copyright © Elsevier Inc.en_HK
dc.subject.meshAgeden_HK
dc.subject.meshChromosome Bandingen_HK
dc.subject.meshChromosomes, Human, Pair 8 - geneticsen_HK
dc.subject.meshCyclophosphamide - adverse effects - therapeutic useen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHumansen_HK
dc.subject.meshIn Situ Hybridization, Fluorescenceen_HK
dc.subject.meshMyelodysplastic Syndromes - chemically induced - complications - geneticsen_HK
dc.subject.meshPulmonary Fibrosis - complications - drug therapy - geneticsen_HK
dc.titlePentasomy 8q in therapy-related myelodysplastic syndrome due to cyclophosphamide therapy for fibrosing alveolitisen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0165-4608&volume=141&issue=1&spage=79&epage=82&date=2003&atitle=Pentasomy+8q+in+therapy-related+myelodysplastic+syndrome+due+to+cyclophosphamide+therapy+for+fibrosing+alveolitis+en_HK
dc.identifier.emailKwong, YL:ylkwong@hku.hken_HK
dc.identifier.authorityKwong, YL=rp00358en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/S0165-4608(02)00661-1en_HK
dc.identifier.pmid12581903en_HK
dc.identifier.scopuseid_2-s2.0-0037308716en_HK
dc.identifier.hkuros76749en_HK
dc.identifier.hkuros88086-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0037308716&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume141en_HK
dc.identifier.issue1en_HK
dc.identifier.spage79en_HK
dc.identifier.epage82en_HK
dc.identifier.isiWOS:000180887400013-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridAu, WY=7202383089en_HK
dc.identifier.scopusauthoridMa, SK=37020910400en_HK
dc.identifier.scopusauthoridWan, TS=25623981600en_HK
dc.identifier.scopusauthoridMan, C=7005722377en_HK
dc.identifier.scopusauthoridKwong, YL=7102818954en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats